Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
20%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Other(2)

Detailed Status

Completed3
unknown2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

completed360%
unknown240%

Recent Activity

0 active trials
Showing 5 of 5
completed

Use of N-Butyl Cyanoacrylate in Transarterial Emergency Embolization

NCT06301919
completed

MYocardial DOmmages Related to COVID-19

NCT04498065
unknown

EPIdemiological Approaches to the Cardiovascular Consequences of COVID-19

NCT04498091
unknown

Radioiodine-avid Bone Metastases From Thyroid Cancer Without Structural Abnormality

NCT04141306
completednot_applicable

Saliva and Plasma Endocannabinoids Concentrations According to Feeding Status and Body Mass Index

NCT01223157

Clinical Trials (5)

Showing 5 of 5 trials
NCT06301919

Use of N-Butyl Cyanoacrylate in Transarterial Emergency Embolization

Completed
NCT04498065

MYocardial DOmmages Related to COVID-19

Completed
NCT04498091

EPIdemiological Approaches to the Cardiovascular Consequences of COVID-19

Unknown
NCT04141306

Radioiodine-avid Bone Metastases From Thyroid Cancer Without Structural Abnormality

Unknown
NCT01223157Not Applicable

Saliva and Plasma Endocannabinoids Concentrations According to Feeding Status and Body Mass Index

Completed

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5